Evin Yucel1, Rasha Al-Bawardy2, Philippe B Bertrand3. 1. Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Yawkey 5E, Boston, MA, 02114, USA. eyucel@partners.org. 2. Cardiac Catheterization Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Yawkey 5E, Boston, MA, 02114, USA.
Abstract
PURPOSE OF REVIEW: Transcatheter edge-to-edge mitral valve repair (TMVr) has been increasingly used in the treatment of patients with severe symptomatic mitral regurgitation who are at high or prohibitive risk for surgical intervention. Pre-existing pulmonary hypertension is known to pertain worse prognosis for patients who are undergoing surgical intervention. The aim of this review is to discuss the current literature on the effects of pulmonary hypertension on the transcatheter edge-to-edge mitral valve repair outcomes. RECENT FINDINGS: Large registry data in patients undergoing TMVr for treatment of severe mitral regurgitation reveal a significant negative impact of baseline pulmonary hypertension on post-procedural outcomes. Pulmonary hypertension is associated with increased mortality and heart failure readmissions in patients undergoing TMVr using MitraClip. Further prospective studies are needed to determine whether earlier intervention will improve clinical outcomes.
PURPOSE OF REVIEW: Transcatheter edge-to-edge mitral valve repair (TMVr) has been increasingly used in the treatment of patients with severe symptomatic mitral regurgitation who are at high or prohibitive risk for surgical intervention. Pre-existing pulmonary hypertension is known to pertain worse prognosis for patients who are undergoing surgical intervention. The aim of this review is to discuss the current literature on the effects of pulmonary hypertension on the transcatheter edge-to-edge mitral valve repair outcomes. RECENT FINDINGS: Large registry data in patients undergoing TMVr for treatment of severe mitral regurgitation reveal a significant negative impact of baseline pulmonary hypertension on post-procedural outcomes. Pulmonary hypertension is associated with increased mortality and heart failure readmissions in patients undergoing TMVr using MitraClip. Further prospective studies are needed to determine whether earlier intervention will improve clinical outcomes.
Authors: S Ghio; A Gavazzi; C Campana; C Inserra; C Klersy; R Sebastiani; E Arbustini; F Recusani; L Tavazzi Journal: J Am Coll Cardiol Date: 2001-01 Impact factor: 24.094
Authors: Hua Yang; William R Davidson; Charles E Chambers; Walter E Pae; Benjamin Sun; David B Campbell; Min Pu Journal: J Am Soc Echocardiogr Date: 2006-08 Impact factor: 5.251
Authors: Vuyisile T Nkomo; Julius M Gardin; Thomas N Skelton; John S Gottdiener; Christopher G Scott; Maurice Enriquez-Sarano Journal: Lancet Date: 2006-09-16 Impact factor: 79.321
Authors: Ted Feldman; Elyse Foster; Donald D Glower; Donald G Glower; Saibal Kar; Michael J Rinaldi; Peter S Fail; Richard W Smalling; Robert Siegel; Geoffrey A Rose; Eric Engeron; Catalin Loghin; Alfredo Trento; Eric R Skipper; Tommy Fudge; George V Letsou; Joseph M Massaro; Laura Mauri Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Andrea Barbieri; Francesca Bursi; Francesco Grigioni; Christophe Tribouilloy; Jean Francois Avierinos; Hector I Michelena; Dan Rusinaru; Catherine Szymansky; Antonio Russo; Rakesh Suri; Maria Letizia Bacchi Reggiani; Angelo Branzi; Maria Grazia Modena; Maurice Enriquez-Sarano Journal: Eur Heart J Date: 2010-09-08 Impact factor: 29.983
Authors: Howard C Herrmann; Saibal Kar; Robert Siegel; Peter Fail; Catalin Loghin; Scott Lim; Rebecca Hahn; Jason H Rogers; William J Bommer; Andrew Wang; Andrew Berke; Stamatios Lerakis; Paul Kramer; S Chiu Wong; Elyse Foster; Don Glower; Ted Feldman Journal: EuroIntervention Date: 2009-01 Impact factor: 6.534
Authors: Julien Magne; Mario Sénéchal; Patrick Mathieu; Jean G Dumesnil; François Dagenais; Philippe Pibarot Journal: J Am Coll Cardiol Date: 2008-04-29 Impact factor: 24.094